MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ecker, G. F.
Right arrow Articles by Chiba, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ecker, G. F.
Right arrow Articles by Chiba, P.

Vol. 61, Issue 3, 637-648, March 2002

Identification of Ligand-Binding Regions of P-Glycoprotein by Activated-Pharmacophore Photoaffinity Labeling and Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry

Gerhard F. Ecker, Edina Csaszar, Stephan Kopp, Brigitte Plagens, Wolfgang Holzer, Wolfgang Ernst, and Peter Chiba

Institutes of Medical Chemistry (P.C., S.K.), Pharmaceutical Chemistry (G.E., B.P., W.H.), Applied Microbiology (W.E.), and the Mass Spectrometry Unit (E.C.), University of Vienna, Austria

Energy dependent efflux pumps confer resistance to anticancer, antimicrobial, and antiparasitic drugs. P-glycoprotein (Pgp, ABCB1) mediates resistance to a broad spectrum of antitumor drugs. Compounds that themselves are nontoxic to cells have been shown to act as inhibitors of Pgp. The mechanism of binding and transport of low-molecular-mass ligands by Pgp is still incompletely understood. This study introduces a series of propafenone-related photoaffinity ligands, which combine high specificity and selectivity for Pgp with high labeling efficiency. Molecules are intrinsically photoactivatable in the arylcarbonyl group, which represents a pharmacophoric substructure for this group of ligand molecules. A detailed study of the structure-activity relationship for this type of photoligand is presented. In subsequent experiments, these ligands were used to characterize the drug-binding domain of propafenone-type analogs. Matrix-assisted laser desorption/ionization---time-of-flight (MALDI-TOF) mass spectrometry shows that propafenone-type ligands preferentially label fragments assigned to putative transmembrane segments 3, 5, 6, 8, 10, 11, and 12. Labeled fragments are also identified in a highly charged region of 15 amino acids in the second cytoplasmic loop. This region corresponds to the so-called EAA-like motif, which has been proposed to play a role in the interaction between transmembrane domain and nucleotide binding domain of peroxisomal ATP-binding cassette transporters. In addition, a region in cytoplasmic loop 3 and between TM12 and the N terminus of the Walker A sequence of NBD2 are labeled by the ligands. Therefore, a number of confined protein regions contribute to the drug-binding domain of propafenone-type analogs.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. W. Loo, M. C. Bartlett, and D. M. Clarke
Insertion of an Arginine Residue into the Transmembrane Segments Corrects Protein Misfolding
J. Biol. Chem., October 6, 2006; 281(40): 29436 - 29440.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
R. G. Deeley, C. Westlake, and S. P. C. Cole
Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins.
Physiol Rev, July 1, 2006; 86(3): 849 - 899.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. Wu, C. J. Oleschuk, Q. Mao, B. O. Keller, R. G. Deeley, and S. P. C. Cole
Analysis of Human Multidrug Resistance Protein 1 (ABCC1) by Matrix-Assisted Laser Desorption Ionization/Time of Flight Mass Spectrometry: Toward Identification of Leukotriene C4 Binding Sites
Mol. Pharmacol., November 1, 2005; 68(5): 1455 - 1465.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Pleban, S. Kopp, E. Csaszar, M. Peer, T. Hrebicek, A. Rizzi, G. F. Ecker, and P. Chiba
P-Glycoprotein Substrate Binding Domains Are Located at the Transmembrane Domain/Transmembrane Domain Interfaces: A Combined Photoaffinity Labeling-Protein Homology Modeling Approach
Mol. Pharmacol., February 1, 2005; 67(2): 365 - 374.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. F. Ecker, K. Pleban, S. Kopp, E. Csaszar, G. J. Poelarends, M. Putman, D. Kaiser, W. N. Konings, and P. Chiba
A Three-Dimensional Model for the Substrate Binding Domain of the Multidrug ATP Binding Cassette Transporter LmrA
Mol. Pharmacol., November 1, 2004; 66(5): 1169 - 1179.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Rothnie, J. Storm, J. Campbell, K. J. Linton, I. D. Kerr, and R. Callaghan
The Topography of Transmembrane Segment Six Is Altered during the Catalytic Cycle of P-glycoprotein
J. Biol. Chem., August 13, 2004; 279(33): 34913 - 34921.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Schmid, D. L. Staudacher, H. G. Loew, P. G. Spieckermann, G. F. Ecker, S. Kopp, and P. Chiba
A Subset of Highly Effective Propafenone-Type Multidrug Resistance Modulators Lacks Effects on Cardiac Action Potential and Mechanical Twitch Parameters of Rat Papillary Muscles
J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 589 - 596.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. W. Loo and D. M. Clarke
Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein
J. Biol. Chem., November 8, 2002; 277(46): 44332 - 44338.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics